RxDoctor Payments Data

Sandria Warren

Primary Care · Montgomery, ALNPI 1841215084

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 252 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 44 manufacturers reported payments, led by Exelixis Inc. at 35.0% of the total. Reporting peaked in 2023 at $3,202 and has fallen 53.1% since, to $1,502 in 2025. Among primary care clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,955in general payments, 2019–2025

Across 252 payments — averaging $27.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$2K
  • Novartis$866
  • Regeneron Healthcare Solutions, Inc.$523
  • Incyte Corporation$294
  • Merck$277
  • Beigene USA, Inc.$204
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$6,955100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,955 in reported general payments places this provider in the 90th percentile of 159 primary care providers in Alabama.

See all primary care providers in Alabama

Medicare billing

Part B allowed, 2024
$40,445
Medicare patients
256
Services billed
532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide30$397,255
EliquisApixaban80$49,631
Imatinib Mesylate15$32,772
XareltoRivaroxaban28$15,122
Enoxaparin Sodium11$4,692
Abiraterone Acetate13$3,303
Anastrozole169$2,788
Entecavir12$2,709
Exemestane24$2,307
Tamoxifen Citrate33$1,028
ValacyclovirValacyclovir Hcl28$812
Hydroxyurea17$573
Potassium Chloride37$369
Ondansetron OdtOndansetron24$276
Letrozole13$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$119$49,63180 claims
Johnson & JohnsonXarelto$99$15,12228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 159 primary care providers in Alabama.

Other primary care in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →